AR064135A1 - Derivados de espiro -piperidina - Google Patents
Derivados de espiro -piperidinaInfo
- Publication number
- AR064135A1 AR064135A1 ARP070105426A ARP070105426A AR064135A1 AR 064135 A1 AR064135 A1 AR 064135A1 AR P070105426 A ARP070105426 A AR P070105426A AR P070105426 A ARP070105426 A AR P070105426A AR 064135 A1 AR064135 A1 AR 064135A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- halo
- halogen
- optionally substituted
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 19
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 13
- 229910052736 halogen Inorganic materials 0.000 abstract 12
- 150000002367 halogens Chemical class 0.000 abstract 12
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 8
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 6
- -1 halo- C1-6 alkoxy Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000005605 benzo group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 229910003827 NRaRb Inorganic materials 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente se refiere a nuevos derivados de indol-2-il-carbonil-espiro-piperidina que actuan como antagonistas del receptor de la V1a, a su obtencion, a composiciones farmacéuticas que los contienen y a su utilizacion como medicamentos. Los compuestos activos de la presente son utiles para la prevencion y el tratamiento de la ansiedad, de trastornos depresivos y de otras enfermedades. Reivindicacion 1: Un compuesto de la formula general (1) en la que X e Y se eligen entre las combinaciones de: X es C=O, e Y es O, X es CH2, e Y es O, X es O, e Y es CH2, X es NR7, e Y es C=O, X es NR7, e Y es CH2, o X-Y es -C=C- o -CH2CH2-; R1 es hidrogeno, alquilo C1-6, opcionalmente sustituido por CN u OH, o -(alquileno C1-6)-C(O)-NRaRb, R2 es hidrogeno, alquilo C1-6, alcoxi C1-6, -(alquileno C1-6)-NRcRd, -(alquileno C1-6)-C(O)Rf, bencilo, opcionalmente sustituido por uno o más halogeno, halo-alquilo C1-6, alquilo C1-6, alcoxi C1-6, halo-alcoxi C1-6, nitro, o ciano, o fenilo, opcionalmente sustituido por uno o más halogeno, haloalquilo C1-6, alquilo C1-6, alcoxi C1-6, halo-alcoxi C1-6, nitro, o ciano; R3 es H, halogeno, o alquilo C1-6; R4 es H, halogeno, alquilo C1-6, halo-alquilo C1-6, alcoxi C1-6, halo-alcoxi C1-6, o - O-alquenilo C2-10; R5 es H, halogeno, alquilo C1-6, o alcoxi C1-6, o R4 y R5 están unidos con el resto benzo para formar un anillo, en el que -R4-R5 es -O-(CH2)n-O-, en el que n es el numero 1 o 2; R6 es H, alquilo C1-6, opcionalmente sustituido por CN u OH, -(alquileno C1-6)-NRgRh, -(alquileno C1-6)-C(O)-NRiRj, -O-bencilo, opcionalmente sustituido por uno o más halogeno, halo-alquilo C1-6, alquilo C1-6, alcoxi C1-6, halo-alcoxi C1-6, nitro, o ciano, nitro, halogeno, ciano, alcoxi C1-6, halo- alcoxi C1-6, halo-alquilo C1-6, -(alquileno C1-6)-C(O)Rf, fenilo opcionalmente sustituido por uno o más halogeno, halo-alquilo C1-6, alquilo C1-6, alcoxi C1-6, halo-alcoxi C1-6, nitro, o ciano, -(alquileno C1-3)-Rm, en el que Rm es fenilo, un heteroarilo de 5 o 6 eslabones, un heterocicloalquilo de 4 a 6 eslabones o un cicloalquilo de 3 a 6 eslabones, cada uno de ellos está opcionalmente sustituido por uno o más halogeno, halo-alquilo C1-6, alquilo C1-6, alcoxi C1-6, halo-alcoxi C1-6, nitro, o ciano; o R5 y R6 están unidos con el resto benzo para formar un anillo, en el que -R5-R6- es -O-(CH2)n-O-, -C(O)-(CH2)n-O-, o -O-(CH2)n-O-, en los que n es el numero 1 o 2; R7 es H o alquilo C1-6; R8, R9, R10, y R11 con independencia entre sí son H, halogeno, alquilo C1-6, halo-alquilo C1-6, alcoxi C1-6 o halo-alcoxi C1-6; Ra, Rb, Ri y Rj con independencia entre sí son: H, alquilo C1-6, -(alquileno C1-6)-NRkRl, en el que Rk y Rl con independencia entre sí son H o alquilo C1-6; o Ra y Rb, o Ri y Rj junto con el átomo de N al que están unidos forman un heterociclo de 5 o 6 eslabones que contiene uno o dos heteroátomos elegidos entre el grupo formado por N, O y S; Rc, Rd, Rg y Rh con independencia entre sí son: hidrogeno, alquilo C1-6, -C(O)Re, o -S(O)2Re, en los que Re se elige entre el grupo formado por: hidrogeno, alquilo C1-6, y fenilo, opcionalmente sustituido por uno o más halogeno, halo-alquilo C1-6, alquilo C1-6, alcoxi C1-6, halo-alcoxi C1-6, nitro, o ciano; o Rc y Rd, o Rg y Rh junto con el átomo de nitrogeno al que están unidos forman un heterociclo de cinco o seis eslabones que contiene uno o dos heteroátomos elegidos entre el grupo formado por nitrogeno, oxígeno y azufre; o Rc y Rd, o Rg y Rh junto con el átomo de nitrogeno al que están unidos forman una isoindol-1,3-diona; Rf se elige entre el grupo formado por: hidrogeno, alquilo C1-6, alcoxi C1-6 y fenilo, opcionalmente sustituido por uno o más halogeno, halo-alquilo C1-6, alquilo C1-6, alcoxi C1- 6, halo-alcoxi C1-6, nitro, o ciano; o una sal farmacéuticamente aceptable de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06125634 | 2006-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064135A1 true AR064135A1 (es) | 2009-03-18 |
Family
ID=39295880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105426A AR064135A1 (es) | 2006-12-07 | 2007-12-05 | Derivados de espiro -piperidina |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20080139554A1 (es) |
| EP (1) | EP2102207B1 (es) |
| JP (1) | JP2010511661A (es) |
| KR (1) | KR101050568B1 (es) |
| CN (1) | CN101547923A (es) |
| AR (1) | AR064135A1 (es) |
| AT (1) | ATE469900T1 (es) |
| AU (1) | AU2007328995B2 (es) |
| BR (1) | BRPI0720004A2 (es) |
| CA (1) | CA2670674A1 (es) |
| CL (1) | CL2007003482A1 (es) |
| DE (1) | DE602007006990D1 (es) |
| ES (1) | ES2344131T3 (es) |
| IL (1) | IL198544A (es) |
| MX (1) | MX2009005504A (es) |
| NO (1) | NO20091830L (es) |
| PE (1) | PE20081252A1 (es) |
| RU (1) | RU2009119394A (es) |
| TW (1) | TW200838518A (es) |
| WO (1) | WO2008068185A1 (es) |
| ZA (1) | ZA200903496B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008077810A2 (en) | 2006-12-22 | 2008-07-03 | F. Hoffmann-La Roche Ag | Spiro-piperidine derivatives |
| EA019601B1 (ru) | 2008-04-29 | 2014-04-30 | Новартис Аг | Производные спироиндола, предназначенные для лечения паразитарных заболеваний |
| SG11201703604VA (en) * | 2014-11-14 | 2017-06-29 | Hoffmann La Roche | Spiro-thiazolones |
| EP3414247B1 (en) * | 2016-02-08 | 2021-04-21 | F. Hoffmann-La Roche AG | Spiroindolinones as ddr1 inhibitors |
| KR102765806B1 (ko) * | 2017-09-05 | 2025-02-10 | 블랙손 테라퓨틱스, 인크. | 바소프레신 수용체 길항제 및 그와 관련된 제품 및 방법 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3370091A (en) * | 1964-06-15 | 1968-02-20 | Hoffmann La Roche | 2 aminobenzhydrylhalides |
| US3531467A (en) * | 1966-12-23 | 1970-09-29 | Hoffmann La Roche | Process for the preparation of 2,3,4,5-tetrahydro - 5 - aryl - 1h - 1,4 - benzodiazepine derivatives |
| US4209625A (en) * | 1977-04-21 | 1980-06-24 | American Hoechst Corporation | Spiro[indoline-3,4'-piperidine]s |
| DE3818830A1 (de) * | 1988-06-03 | 1989-12-14 | Boehringer Mannheim Gmbh | Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel |
| EP0450761A1 (en) | 1990-03-02 | 1991-10-09 | Merck & Co. Inc. | Spirocyclic oxytocin antagonists |
| DK78692D0 (da) | 1992-06-12 | 1992-06-12 | Lundbeck & Co As H | Dimere piperidin- og piperazinderivater |
| JPH08502474A (ja) | 1992-10-07 | 1996-03-19 | メルク エンド カンパニー インコーポレーテッド | トコリティックオキシトシンレセプターアンタゴニスト |
| US5670509A (en) * | 1993-09-27 | 1997-09-23 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| IT1271026B (it) | 1994-10-21 | 1997-05-26 | Isagro Ricerca Srl | Derivati dell'acido b-amminopropionico ad attivita' fungicida |
| US5576321A (en) | 1995-01-17 | 1996-11-19 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| CN1208412A (zh) | 1995-12-14 | 1999-02-17 | 麦克公司 | 促性腺激素释放激素拮抗剂 |
| GB9601724D0 (en) | 1996-01-29 | 1996-03-27 | Merck Sharp & Dohme | Therapeutic agents |
| US6166209A (en) | 1997-12-11 | 2000-12-26 | Hoffmann-La Roche Inc. | Piperidine derivatives |
| CO5150201A1 (es) | 1998-09-07 | 2002-04-29 | Hoffmann La Roche | Derivados de piperidina |
| TWI279402B (en) | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
| GB0003397D0 (en) | 2000-02-14 | 2000-04-05 | Merck Sharp & Dohme | Therapeutic agents |
| CN1174979C (zh) | 2000-05-12 | 2004-11-10 | 索尔瓦药物有限公司 | 哌嗪和哌啶化合物 |
| US7109229B2 (en) | 2000-09-29 | 2006-09-19 | Eli Lilly And Company | Methods and compounds for treating proliferative diseases |
| BR0214455A (pt) | 2001-11-27 | 2004-11-03 | Hoffmann La Roche | Derivados benzotiazol |
| FR2833948B1 (fr) | 2001-12-21 | 2004-02-06 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et leur utilisation en tant que medicament |
| US20040152741A1 (en) | 2002-09-09 | 2004-08-05 | Nps Allelix Corporation | Arylglycine derivatives and their use as glycine transport inhibitors |
| AU2003263155A1 (en) | 2002-09-20 | 2004-04-08 | H. Lundbeck A/S | Method for manufacture of dihydroisobenzofuran derivatives |
| MXPA05003948A (es) | 2002-10-17 | 2005-06-17 | Amgen Inc | Derivados de bencimidazol y su uso como ligandos de receptor vaniloide. |
| AU2003215549A1 (en) | 2003-02-03 | 2004-08-30 | Janssen Pharmaceutica N.V. | Mercaptoimidazoles as ccr2 receptor antagonists |
| US7244852B2 (en) * | 2003-02-27 | 2007-07-17 | Abbott Laboratories | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof |
| EP1615698B1 (en) * | 2003-04-11 | 2010-09-29 | High Point Pharmaceuticals, LLC | New amide derivatives and pharmaceutical use thereof |
| US7504506B2 (en) | 2003-11-04 | 2009-03-17 | Elixir Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| EP1701959A1 (en) * | 2003-12-22 | 2006-09-20 | Pfizer Limited | Triazole derivatives as vasopressin antagonists |
| CA2546147A1 (en) | 2003-12-23 | 2005-07-14 | Arena Pharmaceuticals, Inc. | Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof |
| GB0400700D0 (en) * | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
| CN1993323B (zh) | 2004-08-05 | 2011-04-20 | 霍夫曼-拉罗奇有限公司 | 吲哚，吲唑或二氢吲哚衍生物 |
| EP1802623A1 (en) | 2004-10-12 | 2007-07-04 | Novo Nordisk A/S | 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds |
| WO2006041171A1 (ja) * | 2004-10-13 | 2006-04-20 | Sony Corporation | 再生装置、撮像装置、画面表示方法およびユーザインターフェース |
| JP2008540633A (ja) | 2005-05-18 | 2008-11-20 | ファイザー・リミテッド | バソプレッシン拮抗薬としての１，２，４−トリアゾール誘導体 |
| US8190027B2 (en) * | 2006-07-12 | 2012-05-29 | Tellabs Operations, Inc. | Multifunctional and reconfigurable optical node and optical network |
| DE602006004997D1 (de) * | 2005-07-14 | 2009-03-12 | Hoffmann La Roche | Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors |
| WO2007028638A1 (en) | 2005-09-09 | 2007-03-15 | Euro-Celtique S.A. | Fused and spirocycle compounds and the use thereof |
| WO2008077810A2 (en) * | 2006-12-22 | 2008-07-03 | F. Hoffmann-La Roche Ag | Spiro-piperidine derivatives |
| EP2125827B1 (en) * | 2006-12-29 | 2010-11-03 | F. Hoffmann-La Roche AG | Azaspiro derivatives |
| ATE536356T1 (de) * | 2007-01-12 | 2011-12-15 | Hoffmann La Roche | Spiropiperidin-glycinamid-derivate |
-
2007
- 2007-11-29 AT AT07847502T patent/ATE469900T1/de active
- 2007-11-29 WO PCT/EP2007/062985 patent/WO2008068185A1/en not_active Ceased
- 2007-11-29 AU AU2007328995A patent/AU2007328995B2/en not_active Expired - Fee Related
- 2007-11-29 MX MX2009005504A patent/MX2009005504A/es active IP Right Grant
- 2007-11-29 CN CNA2007800448317A patent/CN101547923A/zh active Pending
- 2007-11-29 DE DE602007006990T patent/DE602007006990D1/de active Active
- 2007-11-29 BR BRPI0720004-8A patent/BRPI0720004A2/pt not_active IP Right Cessation
- 2007-11-29 KR KR1020097011665A patent/KR101050568B1/ko not_active Expired - Fee Related
- 2007-11-29 EP EP07847502A patent/EP2102207B1/en not_active Not-in-force
- 2007-11-29 CA CA002670674A patent/CA2670674A1/en not_active Abandoned
- 2007-11-29 RU RU2009119394/04A patent/RU2009119394A/ru not_active Application Discontinuation
- 2007-11-29 ES ES07847502T patent/ES2344131T3/es active Active
- 2007-11-29 JP JP2009539707A patent/JP2010511661A/ja active Pending
- 2007-11-30 US US11/947,967 patent/US20080139554A1/en not_active Abandoned
- 2007-11-30 US US11/947,934 patent/US20080146568A1/en not_active Abandoned
- 2007-11-30 US US11/947,953 patent/US8202993B2/en not_active Expired - Fee Related
- 2007-12-04 CL CL200703482A patent/CL2007003482A1/es unknown
- 2007-12-04 TW TW096146114A patent/TW200838518A/zh unknown
- 2007-12-05 AR ARP070105426A patent/AR064135A1/es unknown
- 2007-12-06 PE PE2007001736A patent/PE20081252A1/es not_active Application Discontinuation
-
2009
- 2009-05-04 IL IL198544A patent/IL198544A/en not_active IP Right Cessation
- 2009-05-11 NO NO20091830A patent/NO20091830L/no not_active Application Discontinuation
- 2009-05-20 ZA ZA200903496A patent/ZA200903496B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2009119394A (ru) | 2011-01-20 |
| ZA200903496B (en) | 2010-03-31 |
| ES2344131T3 (es) | 2010-08-18 |
| KR101050568B1 (ko) | 2011-07-19 |
| US20080139554A1 (en) | 2008-06-12 |
| TW200838518A (en) | 2008-10-01 |
| MX2009005504A (es) | 2009-06-03 |
| CA2670674A1 (en) | 2008-06-12 |
| EP2102207A1 (en) | 2009-09-23 |
| AU2007328995A1 (en) | 2008-06-12 |
| EP2102207B1 (en) | 2010-06-02 |
| US8202993B2 (en) | 2012-06-19 |
| AU2007328995B2 (en) | 2012-04-26 |
| NO20091830L (no) | 2009-07-06 |
| US20080139553A1 (en) | 2008-06-12 |
| US20080146568A1 (en) | 2008-06-19 |
| IL198544A0 (en) | 2010-02-17 |
| DE602007006990D1 (de) | 2010-07-15 |
| CN101547923A (zh) | 2009-09-30 |
| BRPI0720004A2 (pt) | 2013-12-17 |
| KR20090079255A (ko) | 2009-07-21 |
| JP2010511661A (ja) | 2010-04-15 |
| IL198544A (en) | 2012-06-28 |
| ATE469900T1 (de) | 2010-06-15 |
| CL2007003482A1 (es) | 2008-07-04 |
| WO2008068185A1 (en) | 2008-06-12 |
| PE20081252A1 (es) | 2008-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064136A1 (es) | Derivados de espiro-piperidina, metodos para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas con la accion antagonista del receptor v1a. | |
| AR054327A1 (es) | Fenil-metanonas sustituidas por heterociclos, procesos de preparacion y composiciones farmaceuticas que lo contienen | |
| AR064547A1 (es) | Derivados de azaspiro como antagonistas del receptor v1a | |
| AR064831A1 (es) | Derivados de espiropiperidina-glicinamida | |
| AR057104A1 (es) | Diaminopirimidinas como moduladores de p2 x3 y p2x2 /3 y composicion farmaceutica | |
| AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
| AR067991A1 (es) | Pirrolidina-aril-eteres como antagonistas de receptores de nk3 | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR060604A1 (es) | Nuevos arilamino n- heteroarilos como inhibidores de mek | |
| AR032621A1 (es) | Compuestos derivados de tiofeno, metodo para su preparacion, composicion farmaceutica y uso en la fabricacion de medicamentos | |
| AR040031A1 (es) | Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen | |
| AR046394A1 (es) | Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen. | |
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| AR064137A1 (es) | Derivados de indol-2-il-carbonil-piperidina-benzoimidazolona y de indol-2-il-carbonil-piperidina-benzoxazolona,antagonistas de receptores de vasopresina v1a,metodo de obtencion,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos coronarios,depresivos y otras enfe | |
| AR047098A1 (es) | Derivados de arilanilina como agonistas del receptor adrenergico beta2 | |
| AR064138A1 (es) | Derivados de indol-2-il-carbonil-piperidina, antagonistas de receptores de vasopresina v1a, metodo de obtencion, composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos coronarios, depresivos y otras enfermedades. | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| AR064135A1 (es) | Derivados de espiro -piperidina | |
| AR040126A1 (es) | Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento | |
| AR067075A1 (es) | Derivados de isoxasol - imidazol | |
| AR041246A1 (es) | Derivados de piridina; un procedimiento de preparacion de los mismos y composicion farmaceutica que los contiene | |
| PE20061144A1 (es) | DERIVADOS DE PIRROLIDINA Y PIPERIDINA ACETILENO COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO METABOTROPICO (mGluRs) | |
| PE20242216A1 (es) | Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |